KBC Group NV Has $442,000 Holdings in Repligen Co. (NASDAQ:RGEN)

KBC Group NV trimmed its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 64.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,969 shares of the biotechnology company's stock after selling 5,483 shares during the quarter. KBC Group NV's holdings in Repligen were worth $442,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Oppenheimer Asset Management Inc. raised its holdings in shares of Repligen by 7.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 20,985 shares of the biotechnology company's stock valued at $3,123,000 after acquiring an additional 1,411 shares during the period. Geneva Capital Management LLC grew its position in Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock worth $20,638,000 after purchasing an additional 10,908 shares in the last quarter. WCM Investment Management LLC raised its stake in Repligen by 47.9% during the 3rd quarter. WCM Investment Management LLC now owns 99,158 shares of the biotechnology company's stock valued at $14,470,000 after purchasing an additional 32,126 shares during the period. Versor Investments LP purchased a new stake in shares of Repligen in the third quarter valued at $893,000. Finally, Venturi Wealth Management LLC boosted its position in shares of Repligen by 28.1% in the third quarter. Venturi Wealth Management LLC now owns 1,369 shares of the biotechnology company's stock worth $204,000 after buying an additional 300 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Stock Up 3.5 %

Shares of NASDAQ RGEN traded up $4.56 during mid-day trading on Wednesday, reaching $133.05. 162,243 shares of the company traded hands, compared to its average volume of 666,710. The company's fifty day moving average is $140.30 and its two-hundred day moving average is $143.67. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The stock has a market cap of $7.45 billion, a PE ratio of -358.91, a price-to-earnings-growth ratio of 3.75 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. During the same quarter in the prior year, the business earned $0.23 earnings per share. The company's revenue was up 9.7% on a year-over-year basis. On average, analysts expect that Repligen Co. will post 1.52 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on RGEN shares. Benchmark reissued a "hold" rating on shares of Repligen in a research report on Monday, August 5th. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating for the company. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Wednesday, July 31st. UBS Group dropped their price objective on shares of Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a research note on Wednesday, July 31st. Finally, StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Wednesday, November 13th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.